Bionano Genomics, Inc. (BNGO) Spending and interest coverage
- R&D / revenue · 12 months: Value 40.44%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 11.62%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 40.44% | Research and development expense / revenue. Period ending 2026-06-30. $12.20M ÷ $30.18M × 100 ≈ 40.44% |
| Stock-based compensation / revenue · 12 months | 11.62% | Share-based compensation / revenue. Period ending 2026-06-30. $3.51M ÷ $30.18M × 100 ≈ 11.62% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 12.20M USD | Research and Development Expense |
| Revenue | 30.18M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 3.51M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -32.19M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.20M | $30.18M | $3.51M | $-32.19M | (m) | 40.44% | 11.62% | (m) | (m) |
| 2026-03-31 | $12.14M | $28.74M | $3.62M | $-32.77M | (m) | 42.25% | 12.59% | (m) | (m) |
| 2025-12-31 | $11.37M | $28.51M | $4.53M | $-33.34M | (m) | 39.90% | 15.90% | (m) | (m) |
| 2025-09-30 | $11.62M | $28.72M | $5.54M | $-36.74M | (m) | 40.46% | 19.30% | (m) | (m) |
| 2025-06-30 | $13.49M | $27.43M | $6.80M | $-72.11M | (m) | 49.20% | 24.81% | (m) | (m) |
| 2025-03-31 | $17.39M | $28.46M | $8.31M | $-81.33M | (m) | 61.11% | 29.19% | (m) | (m) |
| 2024-12-31 | $24.80M | $30.78M | $9.74M | $-103.98M | (m) | 80.59% | 31.64% | (m) | (m) |
| 2024-09-30 | $33.03M | $33.33M | $11.17M | $-117.00M | (m) | 99.09% | 33.52% | (m) | (m) |
| 2024-06-30 | $42.09M | $36.58M | $12.96M | $-186.30M | (m) | 115.07% | 35.44% | (m) | (m) |
| 2024-03-31 | $49.87M | $37.47M | $14.31M | $-208.53M | $5.17M | 133.10% | 38.19% | -40.37× | Reported |
| 2023-12-31 | $54.03M | $36.12M | $15.18M | $-215.25M | $5.12M | 149.61% | 42.03% | -42.05× | Reported |
| 2023-09-30 | $56.34M | $33.61M | $17.29M | $-227.82M | $296.00K | 167.63% | 51.43% | -769.66× | Reported |
| 2023-06-30 | $55.30M | $31.51M | $19.35M | $-146.76M | $296.00K | 175.48% | 61.41% | -495.80× | Reported |
| 2023-03-31 | $52.46M | $29.52M | $21.20M | $-139.60M | $297.00K | 177.69% | 71.80% | -470.03× | Reported |
| 2022-12-31 | $49.05M | $27.80M | $22.42M | $-131.70M | $298.00K | 176.42% | 80.63% | -441.94× | Reported |
| 2022-09-30 | $44.25M | $25.89M | $21.74M | $-122.95M | $277.00K | 170.93% | 83.97% | -443.88× | Reported |
| 2022-06-30 | $38.02M | $23.32M | $18.47M | $-111.48M | $207.00K | 163.00% | 79.18% | -538.57× | Reported |
| 2022-03-31 | $30.33M | $20.51M | $14.45M | $-95.88M | $401.00K | 147.91% | 70.46% | -239.10× | Reported |
| 2021-12-31 | $22.48M | $17.98M | $9.72M | $-77.10M | $927.00K | 125.05% | 54.05% | -83.17× | Reported |
| 2021-09-30 | $16.15M | $15.67M | $5.37M | $-59.44M | (m) | 103.05% | 34.26% | (m) | (m) |
| 2021-06-30 | $11.95M | $13.21M | $3.03M | $-48.99M | $1.94M | 90.44% | 22.92% | -25.19× | Reported |
| 2021-03-31 | $10.26M | $10.53M | $1.60M | $-39.95M | $2.30M | 97.39% | 15.16% | -17.40× | Reported |
| 2020-12-31 | $10.26M | $8.50M | $1.55M | $-38.55M | $2.52M | 120.62% | 18.28% | -15.30× | Reported |
| 2020-09-30 | $9.78M | $7.30M | $1.46M | $-34.59M | $2.58M | 133.90% | 19.98% | -13.38× | Reported |
| 2020-06-30 | $9.65M | $8.42M | $1.38M | $-30.04M | $2.65M | 114.58% | 16.35% | -11.34× | Reported |
| 2020-03-31 | $9.65M | $9.41M | $1.39M | $-29.45M | $2.77M | 102.58% | 14.71% | -10.62× | Reported |
| 2019-12-31 | $9.08M | $10.13M | $1.35M | $-25.87M | $2.29M | 89.65% | 13.29% | -11.32× | Reported |
| 2019-09-30 | $9.20M | $11.35M | $2.02M | $-24.81M | $1.68M | 81.06% | 17.82% | -14.74× | Reported |
| 2019-06-30 | $9.53M | $10.87M | $1.71M | $-25.10M | $1.51M | 87.64% | 15.75% | -16.62× | Reported |
| 2019-03-31 | $9.22M | $12.08M | $1.43M | $-22.26M | $1.35M | 76.27% | 11.82% | -16.47× | Reported |
| 2018-12-31 | $9.48M | $12.00M | $1.19M | $-20.42M | $1.38M | 79.03% | 9.95% | -14.78× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $10.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $9.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $12.01M | $9.51M | $382.83K | $-23.22M | $590.93K | 126.35% | 4.03% | -39.29× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |